Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Fulcrum Therapeutics stock

Learn how to easily invest in Fulcrum Therapeutics stock.

Fulcrum Therapeutics Inc is a biotechnology business based in the US. Fulcrum Therapeutics shares (FULC) are listed on the NASDAQ and all prices are listed in US Dollars. Fulcrum Therapeutics employs 104 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Fulcrum Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – FULC – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Fulcrum Therapeutics stock price (NASDAQ: FULC)

Use our graph to track the performance of FULC stocks over time.

Fulcrum Therapeutics shares at a glance

Information last updated 2022-06-24.
Latest market close$4.95
52-week range$3.21 - $33.10
50-day moving average $8.48
200-day moving average $16.01
Wall St. target price$28.38
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-2.39

Buy Fulcrum Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
Finder Award
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
$10
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$1
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$125 - $625
when you open and fund an account with $25,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Axos Bank Self Directed Investing
Stocks
$0
$1,000
$150
when you open an account and deposit at least $1500.
Vanguard Personal Advisor
Stocks, Mutual funds, ETFs
$0
$0
N/A
Financial advice powered by relationships, not commissions.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Fulcrum Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Fulcrum Therapeutics price performance over time

Historical closes compared with the close of $4.95 from 2022-06-29

1 week (2022-06-24) -3.70%
1 month (2022-06-01) -28.47%
3 months (2022-04-01) -79.15%
6 months (2021-12-30) -70.97%
1 year (2021-07-01) -51.85%
2 years (2020-07-01) -71.00%
3 years (2019-06-27) N/A
5 years (2017-06-27) N/A

Fulcrum Therapeutics financials

Revenue TTM $17 million
Gross profit TTM $-46,082,000
Return on assets TTM -29.87%
Return on equity TTM -56.66%
Profit margin 0%
Book value $4.65
Market capitalisation $208.7 million

TTM: trailing 12 months

Fulcrum Therapeutics share dividends

We're not expecting Fulcrum Therapeutics to pay a dividend over the next 12 months.

Fulcrum Therapeutics share price volatility

Over the last 12 months, Fulcrum Therapeutics's shares have ranged in value from as little as $3.21 up to $33.098. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Fulcrum Therapeutics's is 2.5438. This would suggest that Fulcrum Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Fulcrum Therapeutics overview

Fulcrum Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc.

Frequently asked questions

What percentage of Fulcrum Therapeutics is owned by insiders or institutions?
Currently 7.138% of Fulcrum Therapeutics shares are held by insiders and 97.257% by institutions.
How many people work for Fulcrum Therapeutics?
Latest data suggests 104 work at Fulcrum Therapeutics.
When does the fiscal year end for Fulcrum Therapeutics?
Fulcrum Therapeutics's fiscal year ends in December.
Where is Fulcrum Therapeutics based?
Fulcrum Therapeutics's address is: 26 Landsdowne Street, Cambridge, MA, United States, 02139
What is Fulcrum Therapeutics's ISIN number?
Fulcrum Therapeutics's international securities identification number is: US3596161097
What is Fulcrum Therapeutics's CUSIP number?
Fulcrum Therapeutics's Committee on Uniform Securities Identification Procedures number is: 359616109

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site